RAD51 is an important component of double-stranded DNA-repair mechanisms that interacts with both BRCA1 and BRCA2. A single-nucleotide polymorphism (SNP) in the 5 untranslated region (UTR) of RAD51, 135GrC, has been suggested as a possible modifier of breast cancer risk in BRCA1 and BRCA2 mutation carriers. We pooled genotype data for 8,512 female mutation carriers from 19 studies for the RAD51 135GrC SNP. We found evidence of an increased breast cancer risk in CC homozygotes (hazard ratio [HR] 1.92 [95% confidence interval {CI} 1.25-2.94) but not in heterozygotes ;
Germline mutations in BRCA1 (MIM 113705) and BRCA2 (MIM 600185) confer high risks of breast and ovarian cancer. In a meta-analysis of mutation-positive families identified through population-based studies of breast and ovarian cancer cases, the cumulative risks of breast cancer by age 70 years were estimated to be 65% and 45% for BRCA1 and BRCA2 mutation carriers, respectively. 1 However, these and other population-based estimates of penetrance have, in general, been lower than estimates based on families with multiple affected individuals. [2] [3] [4] Moreover, the breast cancer risk has been found to vary by the age at diagnosis and the type of cancer in the index patient. 1, 5 Such observations are consistent with the hypothesis that breast cancer risk in mutation carriers is modified by other genetic or environmental factors that cluster in families. RAD51 is the homolog of bacterial RecA, which is required for recombinational repair of double-strand DNA breaks. 6, 7 Both BRCA1 and BRCA2 interact with RAD51, 8, 9 and the Rad51-knockout mouse phenotype resembles the Brca1-and Brca2-knockout phenotypes. 10 To examine the effect of RAD51 SNPs on cancer risk in BRCA1 and BRCA2 mutation carriers, Wang et al. 11 searched for common sequence variants by resequencing the RAD51 gene. No SNPs in the coding region were identified, but two SNPs (135GrC [rs1801320] and 172GrT [rs1801321]) were discovered in the 5 UTR of RAD51. The latter SNP was found to have no effect on cancer risk, but carriers of the 135C allele were reported to have an increased risk of breast cancer among the subset of BRCA2 carriers ( ; odds n p 216 ratio [OR] 3.2 [95% CI 1.4-40] ). 11 Two additional studies of the 135GrC SNP also found an association with cancer risk in BRCA2 carriers. A study of Israeli Ashkenazi Jewish carriers from 141 BRCA1 families and 64 BRCA2 families found a significant association of the C allele with cancer risk (breast or ovarian) in BRCA2 carriers (hazard ratio [HR] of 4.0 [95% CI 1.3-9.2]), largely because of its effect on breast cancer risk. 12 Kadouri et al. 13 also found an increased risk of breast cancer (HR 2.09 [95% CI 1.04-4.18]) for BRCA2 carriers and reported that the median age at onset of breast cancer in BRCA2 carriers with the RAD51 C allele was 7 years younger than that in RAD51 wild-type carriers.
In contrast, Jakubowska et al. 14 evaluated this RAD51 SNP in a small study of 83 discordant pairs (affected with breast cancer and unaffected) of female carriers of the BRCA1 founder mutation 5382insC and observed a significantly reduced risk of breast cancer among RAD51 135C allele carriers (OR 0.23 [95% CI 0.07-0.62]). In a recent report by the same group, 15 the effect was only marginally significant among the 5382insC carriers (P p ) and became more significant when carriers of the .046 two other BRCA1 Polish founder mutations (4153delA and 300TrG) were included in the analysis (OR 0.58 [95% CI 0.38-0.91];
). P p .018 Studies of genetic modifiers of BRCA1/2 have been hampered by small sample size, such that the power to detect even moderate effects on cancer risk has been limited. To address this problem, we established CIMBA to conduct collaborative analyses of genetic polymorphisms, involving many thousands of samples, as modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers. 16 In this report, we evaluate the association of the RAD51 135GrC polymorphism (rs1801320) with breast cancer risk in BRCA1 and BRCA2 female mutation carriers.
Material and Methods

Study Population
Eligible study subjects were women aged у18 years who carry a pathogenic mutation in BRCA1 or BRCA2. Information on study subjects was submitted from 19 participating studies from 13 countries. These women participated in clinical and research studies at the host institutions under institutional review boardapproved protocols. Data collected included year of birth, mutation description, family membership, ethnicity, country of residence, age at last follow-up, ages at diagnosis of breast and ovarian cancer, and information on bilateral prophylactic mastectomy. Mutations were included in the analysis if they were pathogenic according to generally recognized criteria (from the Breast Cancer Information Core)-that is, (i) mutations generating a premature termination codon as a result of nonsense substitution, frameshift due to small deletion or insertion, aberrant splicing, or large genomic rearrangement (excluding truncating variants in exon 27 of BRCA2); (ii) mutations resulting in loss of expression due to deletion of promoter and transcription start site; (iii) large in-frame deletions spanning one or more exons caused by aberrant splicing or large genomic rearrangement; and (iv) missense mutations classified as pathogenic by use of the algorithms of Goldgar et al. 17 and Chenevix-Trench et al. 18 The functional consequences of pathogenic BRCA1/2 mutations may depend on their type. [19] [20] [21] To examine whether the effect of the RAD51 135GrC on breast cancer risk is different for carriers of different types of BRCA1/2 mutations, we grouped the mutations into two categories. Class 1 corresponds to loss-offunction mutations expected to result in reduced transcript or protein level because of mRNA nonsense-mediated decay (NMD) and/or degradation or instability of truncated proteins, [20] [21] [22] translation reinitiation but no production of stable protein, 23 or the absence of expression because of deletion of transcription regulatory regions. Class 2 consists of mutations likely to generate potentially stable mutant protein that might have dominant negative action, partially preserved normal function, or loss of function. Class 2 mutations are missense substitutions and truncating mutations with premature stop codon occurring in the last exon.
Genotyping
Most centers genotyped the 135GrC SNP in the 5 UTR of RAD51 by the 5 nuclease assay (TaqMan) on an ABI 7900HT Sequence Detection System (Applied Biosystems). PCR primers were forward primer 5 -GCTGGGAACTGCAACTCATCT-3 and reverse primer 5 -GCAGCGCTCCTCTCTCCAGC-3 . Probes were VIC-5 -CAACGCCCGTGGCTTACGCT-3 and FAM-5 -CCCCAACGCCC-CTGGCTTAC-3 . The annealing temperature was 60ЊC. The Interdisciplinary Health Research International Team on Breast Cancer Susceptibility (INHERIT BRCAs) and Iceland LandspitaliUniversity Hospital (ILUH) samples and most of the samples from the Ontario Cancer Genetics Network (OCGN) were genotyped by direct sequencing. INHERIT BRCAs and OCGN used forward primer 5 -GTTTGGCGGGAATTCTGAAAGCCG-3 and reverse primer 5 -GTTCTAAAGACTGAGGTCCACTTG-3 . ILUH used forward primer 5 -TGGGAACTGCAACTCATCTGG-3 and reverse primer 5 -GCGCTCCTCTCTCCAGCAG-3 . GCHBOC used the iCycler technology (Bio-Rad Laboratories) with forward primer 5 -GGGCAAGCGAGTAGAGAAGTG-3 and reverse primer 5 -CGCG-CTCCGACTTCAC-3 . Probes were VIC-5 -CAACGCCCCTGGCTT-3 and FAM-5 -ACGCCCGTGGCTT-3 . The International Hereditary Cancer Centre (IHCC), Helsinki Breast Cancer Study (HEBCS), Deutsche Krebsforschungszentrum (DKFZ), and National Israeli Cancer Center Control (NICCC) used RFLP-PCR analysis, and Memorial Sloan-Kettering Cancer Center (MSKCC) used pyrosequencing (details available on request). All centers included at least 2% of samples in duplicate, no template controls on every plate, and a random mixture of samples of affected and unaffected mutation carriers on each plate. The minimum accepted call rate was 95%. Call rates for each study were in the range 96%-100% (mean 98.5%). There was one discordant result (0.1%) among the 1,008 duplicates genotyped. For each study, the genotype frequencies among unrelated carriers were consistent with the expected frequencies under the assumption of Hardy-Weinberg equilibrium.
All reported CC homozygotes were confirmed by sequencing with use of forward primer 5 -GAGGGCAGTCTGTAAAACTC-3 and reverse primer 5 -AACTGCCGCTGAGCACTGGA-3 . One putative homozygote was shown to be a GC heterozygote by sequencing; for another, there was no DNA available for sequencing, so it was excluded from the analysis. A total of 8,606 mutation carriers with an observed RAD51 135GrC genotype were eligible for inclusion in the study. In some instances, more than one study had enrolled carriers from the same family. We therefore investigated for possible overlap between studies by comparing the year of birth, mutation, and the reported ages, to identify potential duplicate individuals. When a potential duplicate was identified, we contacted the relevant centers for further information about these individuals, without revealing their identity. When potential overlap was identified, centers were contacted to determine precisely the extent of true overlap in subjects and families appearing more than once in the data set. To avoid having families extending over several centers, we excluded the smallest version of the family. In total, 94 carriers with a submitted genotype were excluded: 85 appeared twice in the data set, and 9 were excluded because they were part of the family being studied at another center. The RAD51 135GrC genotypes between the two submissions of the 85 carriers who appeared twice were identical (one was a CC homozygote). A total of 8,512 unique BRCA1 and BRCA2 mutation carriers remained for analysis (table 1) .
Statistical Analysis
Individuals were classified according to their age at diagnosis of breast cancer or their age at last follow-up. For this purpose, individuals were censored at the age at the first of the following events: breast cancer diagnosis ( ), ovarian cancer din p 4,443 agnosis ( ), bilateral prophylactic mastectomy ( ), n p 798 n p 176 or last observation ( ). For the purpose of our analysis, n p 3,095 only carriers censored at breast cancer diagnosis were assumed to be affected. To investigate whether our results were sensitive to the inclusion of prevalent cancer cases, we also performed analyses after excluding patients with breast or ovarian cancer diagnosed 15 years before their age at last follow-up. The 5-year cutoff was selected to maintain a sample size that would still have reasonable power to investigate the effects under consideration, while excluding long-term survivors. Moreover, prognostic data suggest that 5-year survival after breast cancer is ∼95%, so that, within this time frame, survival bias would be minimal. 24 The same cutoff has been used in studies investigating environmental modifiers of risk. 25 For this analysis, we excluded subjects for whom an age at interview was not provided. The IHCC study was also excluded because only a censoring age was provided. This left a total of 5,198 mutation carriers for the sensitivity analysis.
To examine whether our results are modified by consideration of information on bilateral prophylactic oophorectomy (BPO), we also performed analyses whereby carriers were censored at age at BPO. 26 The analysis of associations in BRCA1 and BRCA2 mutation carriers is complicated by the fact that mutation carriers are not randomly sampled with respect to their disease phenotype. Many carriers are sampled through genetic clinics, and it is likely that affected individuals are oversampled. In such cases, standard methods of analysis, like Cox regression, do not give valid estimates of the HRs. 27 To correct for this potential bias, we analyzed the data within a retrospective likelihood framework, by modeling the likelihood of the observed RAD51 135GrC genotypes and disease phenotypes conditional on the disease phenotypes 28 (appendix A). In this model, the breast cancer incidence was assumed to depend on the underlying RAD51 135GrC genotype through a Cox proportional hazards model: ,
where is the HR for genotype i and is the breast cancer exp (b ) l (t) i 0 incidence rate in the baseline category. We estimated the log-HRs for genotypes GC and CC, using the GG homozygotes as the baseline category. The baseline age-specific incidence rates were chosen such that the overall breast cancer incidence rates, averaged over all genotypic categories, agreed with external estimates of BRCA1 and BRCA2 incidence rates. This process is described in detail elsewhere. 29 For this purpose, we used the calendar-specific, cohort-specific (for cohorts based on birth year: before 1920, 1920-1929, 1930-1939, 1940-1949 , and 1950 and after), and age-specific incidence rates derived using combined data from the meta-analysis of the families of BRCA1/2 carriers identified through population-based studies of breast and ovarian cancer 1 and data from three population-based studies of breast cancer [31] [32] [33] [34] [35] (A.C.A., unpublished data). These analyses were performed using the pedigree analysis software MENDEL. 30 We also fitted models in which the log-relative hazards were allowed to vary with age. Significance tests for the null hypothesis that the log-HRs are equal to 0 were also performed using a score test statistic based on the retrospective likelihood described above 36 (also see appendix A). Between-study heterogeneity was examined by comparing the log-likelihood of models with study-specific log-HRs (logL1) against the log-likelihood of models in which the same log-HR was assumed to apply to all studies (logL2). These likelihood-ratio tests are approximate because of the small numbers of carriers in each study and the fact that some parameter estimates converge to boundaries.
All analyses used mutation-, calendar-, and cohort-specific breast cancer incidence rates and were stratified by study, country of residence, and reported ethnicity. Analyses were performed for BRCA1 and BRCA2 mutation carriers combined and separately. Fourteen compound BRCA1 and BRCA2 mutation carriers were included in all analyses. In all instances, a robust variance approach was used to allow for the dependence between related carriers. . To test whether the RAD51 5 UTR isoform 2 was associated with specific alternative splicing of coding exons, we performed RT-PCR by using a forward primer specific to isoform 2 (5 -GAAGTGGAGCTAATGGCAATG-3 ) and a reverse primer in exon 7 (5 -CTGGTGGTCTGTGTTGAACG-3 ). The amplified frag- 
37,38
RNA Extraction and RT-PCR
Quantitative Real-Time PCR Experiments
Experiment 1.-First-strand cDNA synthesis was performed using 1-5 mg of total RNA with Superscript III Rnase H-Reverse Transcriptase (Invitrogen Life Technologies) and oligo-dT 18 . The resulting products were purified with Qiaquick PCR purification kits (QIAGEN). cDNA corresponding to 40-300 ng of total RNA was used to perform fluorescent-based real-time PCR quantification by use of LightCycler FastStart DNA Master Plus SYBR Green I (Roche) on the LightCycler Realtime PCR apparatus (Roche) as described by the manufacturer. The amplification of RAD51 isoform 1 required the addition of 4% DMSO in the reaction mix for PCR. To ensure that a specific fluorescence signal was read, PCRs were brought for 3 s to a temperature a few degrees below the melting temperature of DNA fragments. The fluorescence signal was then registered at this temperature at the end of each cycle (for isoform 1, 84ЊC; for isoform 2, 78ЊC). A melting curve was performed at the end of each run to assess nonspecific signal. The primer pairs used for the specific amplification of RAD51 isoforms were as follows: for RAD51 isoform 1, forward primer 5 -AAGCGAGTAGAGAAGTGGAGCGTA-3 and reverse primer 5 -ACTGCTCTAACCGTGAAATGGG-3 ; for RAD51 isoform 2, forward primer 5 -AGAGAAGTGGAGCTAATGGCAATG-3 and reverse primer 5 -ACTGCTCTAACCGTGAAATGGG-3 . The specificity of isoform 1 primers was also verified by performing PCR with the purified isoform 2 amplicon as a template, and no amplified product was detected. The housekeeping gene glucose-6-phosphate dehydrogenase (G6PD [MIM 305900]) (forward primer 5 -GATGTCCCCTGTCCCACCAACTCTG-3 ; reverse primer 5 -GCA-GGGCATTGAGGTTGGGAG-3 ) was used for normalization. Standard curves were established using serial dilutions of known cDNA amounts for each RAD51 isoform and G6PD, and the expression was quantified as described elsewhere. 39 All experiments were done in duplicate. Experiment 2.-A total of 2 mg of total RNA was reverse transcribed using the First-Strand cDNA Synthesis Kit and pd(N)6 random primers (Amersham Biosciences). Quantification of RAD51 isoform 1 and isoform 2 expression by real-time PCR was performed using LightCycler FastStart DNA Master PLUS SYBR Green I (Roche) on the LightCycler 2.0 instrument (Roche) as described by the manufacturer. Primer pairs used for specific amplification of RAD51 isoforms were as follows: for RAD51 isoform 1, forward primer 5 -GGCCTGCTGGAGAGAGGA-3 and reverse primer 5 -CCACACTGCTCTAACCGTGA-3 ; for RAD51 isoform 2, forward primer 5 -GAAGTGGAGCTAATGGCAATG-3 and reverse primer 5 -CCACACTGCTCTAACCGTGA-3 . A melting curve was performed at the end of each run to assess nonspecific signal. The levels of the reference housekeeping genes glyceraldehyde-3-phosphatase dehydrogenase (GAPDH [MIM 138400]) (forward primer 5 -AGCCACATCGCTCAGACAC-3 and reverse primer 5 -GCCCAATACGACCAAATCC-3 ) and b-actin (ACTB [MIM 102630]) (forward primer 5 -ATTGGCAATGAGCGGTTC-3 and reverse primer 5 -GGATGCCACAGGACTCCAT-3 ) were quantified using TaqMan probes UPL#60 and UPL#11, respectively, and LightCycler Taqman Master (Roche) as described by the manufacturer. All experiments were done in duplicate and were normalized to the geometric mean of the level of these reference genes. Relative standard curves determining the PCR efficiencies of the RAD51 isoforms, GAPDH, and ACTB were established using cDNA serial dilutions. Efficiency-corrected and calibrator-normalized calculations were performed using the LightCycler Relative Quantification Software (Roche). The nonparametric Kruskal-Wallis test was used to test for differences in the distribution of expression levels between genotypes implemented in STATA (version 8.2 for Unix [Statacorp]).
Results
A total of 8,512 BRCA1 and BRCA2 mutation carriers were used in the analysis (tables 1 and 2). The overall RAD51 genotype frequencies (GC 13.3%; CC 0.7%) were similar to those reported in population-based studies in the United Kingdom and Australia, 40, 41 but there was some variation in the frequencies between the CIMBA centers. Carriers of the RAD51 135C allele were least common in the Icelandic (ILUH) study and were most frequent among Polish BRCA1 mutation carriers. The RAD51 genotype frequencies were similar across the larger studies of GEMO, Modifiers and Genetics in Cancer (MAGIC), GCHBOC, EMBRACE, and kConFab.
The genotype frequencies by mutation and disease status are shown in It is well established that BPO significantly reduces the risk of breast cancer among BRCA1 and BRCA2 mutation carriers. 26, 42 We therefore examined whether our results are modified by considering the information on BPO, by censoring carriers at BPO in two ways: mutation carriers with missing information on BPO either were included in the analysis under the assumption that they had not undergone BPO or were excluded from the analysis. When all carriers were used in the analysis, the results were very similar to those of the primary analysis (data not shown). When subjects with missing information on BPO were excluded, the HR among BRCA2 mutation carriers with the GC genotype was estimated to be 1.35 (95% CI 0.97-1.89) and, among BRCA2 carriers with the CC genotype, was estimated to be 5.67 (95% CI 1.64-19.63). Thus, the estimated HRs were comparable to those in the overall analysis, although the effect in the combined sample of BRCA1 and BRCA2 mutation carriers was no longer statistically significant.
Although there are limited experimental data on the functional consequence of BRCA1 and BRCA2 mutations, current evidence suggests that most of the premature stopcodon mutations result in loss of function caused by reduced transcript and protein levels due to NMD and/or instability of the truncated proteins (class 1 mutations). [20] [21] [22] [23] On the other hand, missense or in-frame deletion/insertion mutations, as well as truncating mutations that are not subject to NMD, might generate stable mutant protein that has consequences other than loss of function (class 2 mutations). It is possible that the BRCA1/2 mutations in these two categories may interact in different ways with the potential cancer risk modifier effect of RAD51 135GrC. Of the BRCA1 mutation carriers, 64% carried class 1 mutations, 33% carried class 2 mutations, and 3% carried mutations of unpredictable consequence at transcript or protein level. The majority (95%) of the BRCA2 mutation carriers carried class 1 mutations. There was some indication that the RAD51 135GrC genotype association was greater in carriers of class 1 BRCA1 mutations, with an estimated HR among CC homozygotes of 1.97 (95% CI 1.05-3.70; ), and had no effect in P p . ). SNP rs10518696 is in an intron, and SNPs rs8034726 and rs16970854 are in the promoter region. CASC5 (also known as "AF15Q14" and "D40") is a component of the hMis12 kinetochore complex essential for chromosome segregation 43 and is fused to the MLL gene as a result of translocations in some cases of acute lymphoblastic and myeloblastic leukemias. [44] [45] [46] However, there is no known interaction between CASC5 and BRCA1 or BRCA2, so we consider RAD51 to be the more plausible modifier of risk.
The molecular mechanism by which the RAD51 135GrC SNP results in increased breast cancer risk in BRCA2 mutation carriers is unclear. Alternative splicing of the human RAD51 gene, involving coding and noncoding exons, has been reported in genomic databases (including GenBank). Some mRNAs had 5 UTRs shorter than the 5 UTR of the full-length RAD51 transcript (GenBank accession number NM_002875), with 135GrC located 1 nt next to the canonical motif of the alternative 5 splice site within the 5 UTR (fig. 1A) .
To investigate whether 135GrC is involved in the regulation of the pattern of the 5 UTR alternatively spliced RAD51 transcripts, we examined their relative abundance in lymphoblastoid cell lines established from 5 CC homozygotes, 20 GC heterozygotes, and 20 GG homozygotes by performing RT-PCR, encompassing the 5 UTR, exon 1, and exon 2, including the beginning of the coding region ( fig. 1A and 1B) . Several RAD51 transcripts with varying length for the 5 UTR were detected. The two predominant RAD51 transcripts had the longest and the shortest 5 UTRs: isoform 1 (full-length 5 UTR of 257 nt [GenBank accession number NM_002875]) and isoform 2 (truncated 5 UTR of 153 nt [GenBank accession number AK131299]), generated by an alternative splicing within the 5 UTR, which removes the 104-nt 5 UTR sequence recognized as part of intron 1. These RT-PCR experiments suggested that the level of the isoform 2 transcript varied between cell lines with different 135GrC genotypes and was found to be particularly low in CC homozygotes (fig. 1B) . To investigate this observation further, we used quantitative real-time PCR to compare the expression of the RAD51 isoforms 1 and 2 across three 135GrC genotypes. The quantitative real-time PCR quantification was performed in two laboratories with overlapping sets of samples, by use of different housekeeping genes for normalizing the RAD51 expression data. The results between the two experiments were very similar and are shown in detail in figure 2 . There was no statistically significant difference in the expression levels for isoform 1 among the three genotypes (experiment 1, ; experiment 2, P p .92 P p ), but there were significant differences among the ge-.44 notypes in the expression of isoform 2 (experiment 1, ; experiment 2, ). Pairwise genotype P p .008 P p .001 comparisons of the mean expression levels of isoform 2 revealed 3-7-fold differences between GG and CC homozygotes (experiment 1, ; experiment 2, P p .007 P p ) and 2-4-fold differences between GC heterozygotes .002 and CC homozygotes (experiment 1, ; experi-P p .012 ment 2,
). There were no statistically significant P p .002 differences between the expression levels of isoform 2 between GG homozygotes and GC heterozygotes (experiment 1, ; experiment 2, ). P p .137 P p .087 To test whether the RAD51 5 UTR isoform 2 is associated with specific alternative splicing of coding exons and may, therefore, give rise to a variant RAD51 protein, we performed RT-PCR, using the forward primer specific to isoform 2 and the reverse primer in exon 7 (see the "Material and Methods" section), generating an amplicon covering the RAD51 exons reported to be alternatively spliced. However, no isoform 2 transcripts with alternative splicing of coding exons were detected.
To find out whether alternative RAD51 splicing that produces isoforms 1 and 2 transcripts is present in mammary gland and is not limited to lymphoblastoid cell lines, we studied human mammary epithelial cells and four human breast cancer cell lines: MCF-7, MDA-MB-157, ZR-75-1, and T47D. Both isoforms 1 and 2 were detected in the breast epithelium and cancer samples tested (data not shown).
Discussion
In this study, we combined data from 19 studies to investigate the effect of the RAD51 135GrC SNP on breast cancer risk among BRCA1 and BRCA2 female mutation carriers and found evidence that this polymorphism is associated with breast cancer risk among BRCA2 mutation carriers ( , by trend test; , by 2-df test). P p .007 P p .0007 We found no evidence of a higher risk in GC heterozygotes, and the sample size was sufficient to rule out any However, we found strong evidence of an increased risk in CC homozygotes (HR 3.18 [95% CI 1.39-7.27]). The association with breast cancer risk was weaker or nonexistent in BRCA1 carriers, but larger studies will be needed to determine whether there is any association in this group.
Since CC homozygotes are rare, previous studies would have been too small to detect this effect. Only a study of this size, made possible through the CIMBA collaboration, allows such effects to be detected reliably. The association with risk in BRCA2 carriers was essentially unaltered by restriction to incident cases and by adjustment for prophylactic oophorectomy.
There was some evidence of heterogeneity in the HRs between the studies for BRCA2 mutation carriers. However, this may be partly because of the very small number of rare homozygotes in each study, which results in imprecise study-specific estimates. Studies with larger numbers of BRCA2 mutation carriers are required to clarify this further.
Three previously published studies found evidence that carriers of the 135C allele among BRCA2 mutation carriers were at a significantly increased risk of breast cancer, [11] [12] [13] with the evidence largely coming from the heterozygotes. Although the data from one of these studies are included in the current combined CIMBA analysis 11 and although partial overlap may exist with the other two studies, which we cannot establish with certainty, we did not find significant evidence of an increased risk among the heterozygotes.
Two additional studies investigated the effect of the RAD51 135GrC polymorphism among Polish BRCA1 mutation carriers and found a significant protective effect among carriers of the 135C allele. 14, 15 These data were included in the CIMBA analysis (as a subset of the IHCC study), but the combined analysis does not support this finding. This discrepancy may reflect differences in the eligibility criteria for participation in each study, differences in the study size, or differences in the statistical methods used. In the present analysis, the IHCC studyspecific HR estimates were not significantly different from 1 for either the heterozygotes or the rare homozygotes. Interestingly, 93% of the carriers in the IHCC group carry BRCA1 class 2 mutations, for which no effect was detected in our analysis.
The effect of the RAD51 135GrC SNP in unselected series of breast cancer cases has been investigated in a small number of studies. Kuschel et al. 40 found no significant association with breast cancer among heterozygote carriers, whereas the OR estimate for rare homozygotes was 2.5 (95% CI 0.6-10.9). However, preliminary analyses of a larger sample from the same population found an OR of 0.97 (95% CI 0.45-2.07) among the CC homozygotes (K. Pooley, personal communication). Another population-based study from Australia also found no evidence of association with breast cancer risk. 41 These observations raise the possibility that the association between RAD51 135GrC and breast cancer risk is specific to BRCA2 carriers.
BRCA2 mediates the homologous recombination activity of RAD51 through binding to this DNA recombinase and is essential for the repair of DNA double-strand breaks. 6, 47 The effect on breast cancer risk observed in our study suggests an interaction between the functional outcomes of the RAD51 135C allele and BRCA2-inactivating mutations. Because of the strong linkage disequilibrium in this region, genetic studies cannot distinguish whether the association is being driven by RAD51 135GrC itself or by other polymorphisms in the region (including CASC5), but RAD51 135GrC is the most plausible causative variant. Prior characterization of RAD51 suggested that it contains a 747-nt basic promoter region that includes the 135GrC polymorphic site. 48 Furthermore, expression constructs containing the 135C allele had higher activity than that of the wild type.
Our study suggests an effect of the RAD51 135GrC variant on the RAD51 alternative splicing within the 5 UTR. The level of the RAD51 alternative isoform 2 transcript is significantly decreased in the lymphoblastoid cell lines of 135CC homozygotes, compared with other genotypes. Interestingly, the part of the 5 UTR sequence that is lacking in isoform 2 has a particularly high GC content (77%) and is predicted to create highly stable stem-loop secondary structures (RNA and DNA Folding Applications). 49 Such structures are known to negatively regulate the translation potential, by inhibiting binding or scanning of the translation machinery. 50, 51 Therefore, isoform 2 would be expected to have high translation efficiency. These findings suggest that the RAD51 135C allele may cause an overall lower abundance of RAD51 protein, thereby providing an insight into the molecular mechanism through which this RAD51 variant may affect cancer risk. Further studies will be needed to characterize the consequences of this SNP at the protein level, particularly in breast tissue.
The identification of RAD51 as a genetic modifier may have implications for the clinical management of BRCA2 mutation carriers. On the basis of the estimated HR in CC homozygotes, the estimated absolute risk of breast cancer in BRCA2 carriers by age 70 years in the most recent birth cohort would be 90% in CC homozygotes, compared with 51% in GG homozygotes. This difference may be sufficiently large to alter management for those rare patients who are RAD51 CC homozygotes. BRACE 
